Suppr超能文献

相似文献

1
Sirt1 protects from K-Ras-driven lung carcinogenesis.
EMBO Rep. 2018 Sep;19(9). doi: 10.15252/embr.201643879. Epub 2018 Jul 18.
3
JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
Int J Cancer. 2019 Dec 15;145(12):3376-3388. doi: 10.1002/ijc.32624. Epub 2019 Sep 10.
4
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.
Exp Mol Med. 2023 Oct;55(10):2220-2237. doi: 10.1038/s12276-023-01091-0. Epub 2023 Oct 2.
5
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
J Exp Clin Cancer Res. 2019 Apr 15;38(1):165. doi: 10.1186/s13046-019-1170-7.
9
Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma.
Cancer Cell. 2013 Nov 11;24(5):603-16. doi: 10.1016/j.ccr.2013.10.003.
10
ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
Cancer Gene Ther. 2021 May;28(5):359-374. doi: 10.1038/s41417-020-00245-w. Epub 2020 Oct 17.

引用本文的文献

1
Senotherapy for chronic lung disease.
Pharmacol Rev. 2025 May 28;77(4):100069. doi: 10.1016/j.pharmr.2025.100069.
2
SLC29A1 and SLC29A2 are human nicotinamide cell membrane transporters.
Nat Commun. 2025 Jan 30;16(1):1181. doi: 10.1038/s41467-025-56402-y.
3
Emerging role of sirtuins in non‑small cell lung cancer (Review).
Oncol Rep. 2024 Oct;52(4). doi: 10.3892/or.2024.8786. Epub 2024 Aug 2.
4
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.
Exp Mol Med. 2023 Oct;55(10):2220-2237. doi: 10.1038/s12276-023-01091-0. Epub 2023 Oct 2.
5
From targeted therapy to a novel way: Immunogenic cell death in lung cancer.
Front Med (Lausanne). 2022 Dec 23;9:1102550. doi: 10.3389/fmed.2022.1102550. eCollection 2022.
7
Resveratrol's Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism.
Cancers (Basel). 2021 Jan 7;13(2):188. doi: 10.3390/cancers13020188.
8
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.
Front Cell Dev Biol. 2020 Sep 29;8:576946. doi: 10.3389/fcell.2020.576946. eCollection 2020.
9
Avenanthramide C suppresses hypoxia-induced cyclooxygenase-2 expression through sirtuin1 activation in non-small-cell lung cancer cells.
Anim Cells Syst (Seoul). 2020 Apr 2;24(2):79-83. doi: 10.1080/19768354.2020.1748108. eCollection 2020.
10
ERK Dephosphorylation through MKP1 Deacetylation by SIRT1 Attenuates RAS-Driven Tumorigenesis.
Cancers (Basel). 2020 Apr 8;12(4):909. doi: 10.3390/cancers12040909.

本文引用的文献

1
Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer.
Exp Cell Res. 2018 Feb 1;363(1):121-128. doi: 10.1016/j.yexcr.2017.12.020. Epub 2017 Dec 23.
2
Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.
J Biol Chem. 2018 Feb 2;293(5):1794-1809. doi: 10.1074/jbc.M117.815902. Epub 2017 Dec 15.
4
Analysis of the advantages of cis reporters in optimized FACS-Gal.
Cytometry A. 2017 Jul;91(7):721-729. doi: 10.1002/cyto.a.23086. Epub 2017 Apr 4.
5
Prognostic and Predictive Role of Sirtuin1 Expression in Lung Adenocarcinoma.
Clin Lab. 2016 Oct 1;62(10):1989-1994. doi: 10.7754/Clin.Lab.2016.160317.
7
Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers.
Science. 2016 Sep 9;353(6304):1161-5. doi: 10.1126/science.aaf5171.
8
FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies.
Cell Death Discov. 2015 Nov 23;1:15049. doi: 10.1038/cddiscovery.2015.49. eCollection 2015.
9
Oncogenic driver mutations in lung cancer.
Transl Respir Med. 2013 Dec;1(1):6. doi: 10.1186/2213-0802-1-6. Epub 2013 Mar 8.
10
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
Mol Cancer. 2016 Feb 3;15:12. doi: 10.1186/s12943-016-0494-6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验